

# CITATION REPORT

List of articles citing

Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults

DOI: 10.1016/j.vaccine.2018.01.049  
Vaccine, 2018, 36, 1477-1483.

**Source:** <https://exaly.com/paper-pdf/68987636/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
29	[Adult community acquired pneumonia vaccination: 2018 Update of the positioning of the Pneumonia Prevention Expert Group]. <i>Semergen</i> , <b>2018</b> , 44, 590-597	1.9	0
28	Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. <i>PLoS ONE</i> , <b>2018</b> , 13, e0199427	3.7	3
27	Progress in mucosal immunization for protection against pneumococcal pneumonia. <i>Expert Review of Vaccines</i> , <b>2019</b> , 18, 781-792	5.2	5
26	Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis. <i>Vaccine</i> , <b>2019</b> , 37, 6310-6316	4.1	24
25	Latin American Adult Immunisation Advocacy Summit: Overcoming regional barriers to adult vaccination. <i>Aging Clinical and Experimental Research</i> , <b>2019</b> , 31, 339-344	4.8	4
24	Paediatric and adult bronchiectasis: Vaccination in prevention and management. <i>Respirology</i> , <b>2019</b> , 24, 107-114	3.6	3
23	Pneumococcus-Still an Opportunist for People Living With Human Immunodeficiency Virus-Now What?. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 71, 51-52	11.6	
22	Early Impact of 13-Valent Pneumococcal Conjugate Vaccine Use on Invasive Pneumococcal Disease Among Adults With and Without Underlying Medical Conditions-United States. <i>Clinical Infectious Diseases</i> , <b>2020</b> , 70, 2484-2492	11.6	26
21	Cost-effectiveness of continuing pneumococcal conjugate vaccination at age 65 in the context of indirect effects from the childhood immunization program. <i>Vaccine</i> , <b>2020</b> , 38, 1770-1777	4.1	16
20	Targeting Inflammation and Immunosenescence to Improve Vaccine Responses in the Elderly. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 583019	8.4	38
19	Respiratory Syncytial Virus-associated Acute Otitis Media in Infants and Children. <i>Journal of the Pediatric Infectious Diseases Society</i> , <b>2020</b> , 9, 544-550	4.8	1
18	Vaccines to Prevent Infectious Diseases in the Older Population: Immunological Challenges and Future Perspectives. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 717	8.4	34
17	A Systematic Review of Studies Published between 2016 and 2019 on the Effectiveness and Efficacy of Pneumococcal Vaccination on Pneumonia and Invasive Pneumococcal Disease in an Elderly Population. <i>Pathogens</i> , <b>2020</b> , 9,	4.5	13
16	Pneumonia in older adults. <i>Current Opinion in Infectious Diseases</i> , <b>2021</b> , 34, 135-141	5.4	2
15	Pneumococcal Pneumonia and Invasive Pneumococcal Disease in Those 65 and Older: Rates of Detection, Risk Factors, Vaccine Effectiveness, Hospitalisation and Mortality. <i>Geriatrics (Switzerland)</i> , <b>2021</b> , 6,	2.2	2
14	A phase 3, multicenter, single-arm, open-label study to assess the safety, tolerability, and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine in Japanese participants aged 6-64 years who are considered to be at increased risk of pneumococcal disease and who are naive to pneumococcal vaccines. <i>Vaccine</i> , <b>2021</b> , 39, 6414-6421	4.1	0
13	Cost-effectiveness of implementing 13-valent pneumococcal conjugate vaccine for U.S. adults aged 19 years and older with underlying conditions. <i>Human Vaccines and Immunotherapeutics</i> , <b>2021</b> , 17, 2232-2240	4.4	4

12	CONSENSUS STATEMENT INTERSOCIETARIA: VACCINAZIONI RACCOMANDATE NEL PAZIENTE DIABETICO ADULTO. <i>Il Diabete</i> , <b>2018</b> , 30,	0	0
11	Vaccines and Biologics. <b>2017</b> ,		
10	Efficacy of 13-valent pneumococcal conjugate vaccine in healthcare workers. <i>Terapevticheskii Arkhiv</i> , <b>2018</b> , 90, 55-61	0.9	1
9	Vacunaci3 neumoc3ica conjugada en adultos. Recomendaciones de las Sociedades M3icas en M3xico. <b>2019</b> , 78, 152-173		
8	Tetrahydropyrimidines, ZL-5015 Alleviated Lipopolysaccharide (LPS)-Induced Acute Pneumonia in Rats by Activating the NRF-2/HO-1 Pathway. <i>Medical Science Monitor</i> , <b>2020</b> , 26, e924482	3.2	0
7	Multi-disciplinary Consensus Statement Document Vaccinal prevention in adult patients with diabetes mellitus. <i>Journal of Preventive Medicine and Hygiene</i> , <b>2018</b> , 59, E249-E256	1.4	2
6	Vaccines and Vaccination Strategies for Older Adults. <i>Healthy Ageing and Longevity</i> , <b>2022</b> , 119-164	0.5	0
5	PCV13 Vaccination of Adults against Pneumococcal Disease: What We Have Learned from the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).. <i>Microorganisms</i> , <b>2022</b> , 10,	4.9	2
4	A case for implementation of adult pneumococcal vaccine program in Africa: review and expert opinion.. <i>Pan African Medical Journal</i> , <b>2022</b> , 41, 51	1.2	
3	Immune response to vaccination in the elderly. <i>Vnitřni Lekarstvi</i> , <b>2021</b> , 67, E14-E18	0.3	0
2	Immunogenicity of a 20-valent pneumococcal conjugate vaccine in adults 18 to 64 years old with medical conditions and other factors that increase risk of pneumococcal disease.		0
1	Increased Risk of Hospitalization for Pneumonia in Italian Adults from 2010 to 2019: Scientific Evidence for a Call to Action. <b>2023</b> , 11, 187		0